Sinclair Pharma?s financial year has successfully drawn to an end with an extensive number of regulatory approvals in both the US and EU, 31 commercial agreements signed worldwide over the period, and a company acquisition in Italy.

Unlock this Article with a 14 day free trial

or Unlock with your email

Already have an account?
Login here